Aptamer - Wikipedia
A typical aptamer is a synthetically generated ligand exploiting the combinatorial diversity of DNA, RNA, XNA, or peptide to achieve strong, specific binding for a particular target molecule or family of target molecules. Aptamers are occasionally classified as "chemical antibodies" or …
核酸适配体（Aptamer）VS 抗体（Antibody） - 知乎专栏
核酸适配体 (Aptamer) 是一种经体外筛选技术-指数富集的配体系统进化技术（Systematic evolution of ligands by exponential enrichment，SELEX），得到的结构化的寡核苷酸序列 (RNA或 DNA)，与相应的靶标分子（蛋白质，病毒，细菌，细胞，重金属离子等）有严格的识别能 …
核酸适配体 - 百度百科
核酸 适配体（Aptamer）是一段 寡核苷酸 序列（ DNA 或 RNA ）。 通常是利用体外筛选技术——指数富集的配体系统进化技术（Systematic evolution of ligands by exponential enrichment， SELEX ），从核酸分子文库中得到的寡核苷酸片段。
核酸适配体（Aptamer）是什么？ - 知乎专栏
核酸适配体(Aptamer)是一种能和靶分子特异性结合的单链寡核苷酸。 核酸适配体识别靶分子的原理：单链寡核苷酸通过核苷酸碱基互补配对、氢键、π-π堆积、静电作用力等多种相互作用力发生自身适应性折叠后形成特定…
Aptamers as targeted therapeutics: current potential and ... - Nature
Nov 3, 2016 · Six RNA and four DNA aptamers have undergone clinical trials for the treatment of various conditions, including macular degeneration, coagulation, oncology and inflammation.
Analysis of aptamer discovery and technology - Nature
Oct 4, 2017 · Although the dominant backbone chain used for aptamer discovery is DNA-based (>50%) — chosen presumably for its increased chemical and biological stability relative to RNA, commercial ...
Development of DNA aptamers using Cell-SELEX - Nature
Jun 3, 2010 · This protocol, cell-SELEX (systematic evolution of ligands by exponential enrichment), is a method that can generate DNA aptamers that can bind specifically to a cell type of interest.
Current Perspectives on Aptamers as Diagnostic Tools and …
Jul 9, 2020 · Recently, there is a growing interest in developing aptamers that target cancer-cell surface proteins and biomarkers and further translate them into clinical trials. The first DNA aptamer for cancer treatment was AS1411, targeted for the nucleolin protein.
Recent Advances in Aptamer Discovery and Applications
Mar 7, 2019 · AS1411, a G-rich DNA aptamer against nucleolin, is undergoing phase II clinical trial for acute myeloid leukemia. The anti-tumor activity of AS1411 stems from its ability to bind cell surface nucleolin, thereby inhibiting DNA synthesis, preventing cell growth signaling, and inducing apoptosis .
Aptamers: A Review of Their Chemical Properties and …
Nov 21, 2019 · To achieve this goal, several features of the aptamer are required. First, therapeutic aptamers should be highly stable in the body. Since natural RNA and DNA are susceptible to endogenous nucleases, chemical modifications on the sugar and/or phosphodiester backbone should be adequately included (Figure 2).